Novo Nordisk A/S (NVO) , 선행 이익수익률 53.19%. PEG 0.24 (Peter Lynch 저평가 ≤1.0).
이 페이지에서 입증된 기준:
SharesGrow 종합 점수: 81/100 5/7 개 기준 통과.
| Year | EPS (희석) | 매출 | 순이익 | 순이익률 |
|---|---|---|---|---|
| 2016 | $7.48 | $111.78B | $37.93B | 33.9% |
| 2017 | $7.70 | $111.7B | $38.13B | 34.1% |
| 2018 | $7.97 | $111.83B | $38.63B | 34.5% |
| 2019 | $8.19 | $122.02B | $38.95B | 31.9% |
| 2020 | $9.01 | $126.95B | $42.14B | 33.2% |
| 2021 | $10.37 | $140.8B | $47.76B | 33.9% |
| 2022 | $12.22 | $176.95B | $55.53B | 31.4% |
| 2023 | $18.62 | $232.26B | $83.68B | 36% |
| 2024 | $22.63 | $290.4B | $100.99B | 34.8% |
| 2025 | $23.03 | $297.2B | $98.5B | 33.1% |
| Year | EPS (평균) | EPS 범위 | 매출 (평균) | 매출 범위 | 애널리스트 수 |
|---|---|---|---|---|---|
| 2026 | $20.89 | $19.53 – $23.13 | $287.9B | $277.94B – $311.52B | 5 |
| 2027 | $21.54 | $19.14 – $24.83 | $302.89B | $288.52B – $325.94B | 8 |
| 2028 | $23.41 | $21.26 – $26.52 | $322.76B | $300.01B – $355.8B | 7 |
| 2029 | $25.77 | $23.41 – $29.20 | $342.51B | $318.36B – $377.57B | 6 |
| 2030 | $28.14 | $25.56 – $31.89 | $366.25B | $340.43B – $403.75B | 6 |
